BSE filing, NSE: GVBL. Summary written from the filing by ALFA Finder's alert engine.
Genomic Valley Biotech Ltd: key numbers
- Share price
- ₹43.63
- Market cap
- ₹13.33 Cr
- Revenue (annual)
- ₹0.27 Cr
- Net profit (annual)
- ₹0.03 Cr
- P/E (TTM)
- 655.2×Sector 46.5×
- Promoter holding
- 46.06%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Genomic Valley Biotech Ltd
All →Genomic Valley Biotech Open Offer: ₹57.97 Cr
Manager to the Open Offer filed GVB's DPS announcing an open offer for up to 7,94,170 shares at ₹730. The Acquirers seek about 21% of the company.
- Value
- ₹57.97 Cr
Genomic Valley Biotech Board Meeting Date
Board meeting scheduled for October 30, 2026, to consider unaudited Q2 and H1 FY27 financial results. Trading window closed pending results publication.
Genomic Valley Biotech Merger & Restructuring
Promoter Yogesh Agrawal has entered into a Share Purchase Agreement to sell his entire 46.06% stake in Genomic Valley Biotech to Pankaj Grover and Abhisek Gupta.
Genomic Valley Biotech Open Offer: ₹2.38 Cr
Acquirers Pankaj Grover and Abhisek Gupta announced an open offer for 7.94 lakh shares of Genomic Valley Biotech Ltd at ₹30 per share.
- Value
- ₹2.38 Cr
Genomic Valley Biotech Other Announcement
Genomic Valley Biotech Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. This mandatory disclosure provides details on the company's shareholding structure.
Genomic Valley Biotech Other Announcement
Genomic Valley Biotech Limited received approval from the Registrar of Companies to extend the AGM deadline for FY26 to 31st December 2026. This is a regulatory compliance update.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.